1
|
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
|
Br J Haematol
|
2006
|
1.56
|
2
|
Natural history of osteonecrosis of the jaw in patients with multiple myeloma.
|
J Clin Oncol
|
2008
|
1.01
|
3
|
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
|
Leuk Res
|
2006
|
0.92
|
4
|
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
|
Am J Hematol
|
2013
|
0.91
|
5
|
Evaluation of five staging systems in 470 patients with multiple myeloma.
|
Haematologica
|
2006
|
0.80
|
6
|
Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina.
|
Br J Haematol
|
2003
|
0.78
|
7
|
On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
|
Br J Haematol
|
2002
|
0.77
|
8
|
Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
|
Hematology
|
2007
|
0.76
|
9
|
Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma.
|
Lab Hematol
|
2006
|
0.75
|